Adrian Towse
Adrian is an economist, focussing on the use of value–based pricing in drug/ vaccine reimbursement and the economics of innovation. He is a Visiting Professor in Practice at the London School of Economics.
Adrian’s current research interests include incentives for new drugs and vaccines to tackle Antimicrobial Resistance; the use of ‘risk– sharing’ arrangements between health care payers and pharmaceutical companies, measuring novel elements of value and the use of value–based pricing; the economics of stratified medicine for health care payers and the pharmaceutical industry; and economic issues that affect both R&D for and access to treatments for diseases prevalent in the low and middle income countries.
Publications and Insights
- Insight: R&D For New Drugs To Tackle AMR Is A High Return Investment For All EU Member States
- Insight: Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
- Insight: Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
- Insight: OHE’s AMR consultation response
- Insight: New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
- Publication: A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance
- Publication: Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
- Insight: G7 Investments in New Antibiotics Would Pay Off – For Everyone
- Publication: Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies
- Insight: The World Needs New Antibiotics. A Proposed US Program to Develop Them Offers a High Pay-Off
- Insight: The Economics of Antibiotics – Part 4: What Does the Antibiotics Market of the Future Look Like?
- Insight: The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics
- Insight: The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot
- Insight: The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance
- Publication: Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
- Insight: Would Waiving COVID-19 Vaccines Patents Save Lives?
- Publication: It Takes Two to Tango: When do Conditional Reimbursement Risk-Sharing Schemes Work for Both Parties?
- Publication: Working Towards a Sustainable, Healthy Market for Vaccines: a Comprehensive Framework to Support Policy Dialogue and Decision-Making
- Publication: Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
- Publication: Key Factors on How to Procure, Pay, Distribute and Use Vaccines for COVID-19: A European Perspective
- Publication: Exploring the Financial Sustainability of Gene Therapies
- Publication: Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
- Publication: Cornerstones of “Fair” Drug Coverage: Appropriate Cost – Sharing and Utilization Management Policies for Pharmaceuticals
- Publication: A Bargaining Approach: A Theory on ICER Pricing and Optimal Level of Cost-Effectiveness Threshold
- Publication: How Should the World Pay for a COVID-19 Vaccine?
- Publication: Indication-Based Pricing (IBP) Consultation Report
- Publication: Data Governance Arrangements for Real-World Evidence in Japan
- Publication: HTA and Payment Mechanisms for New Drugs to Tackle AMR
- Publication: The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK
- Publication: Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
- Publication: Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
- Publication: The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment
- Publication: Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
- Publication: Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
- Publication: The Future of Global Health Procurement: Issues around Pricing Transparency
- Publication: Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward
- Publication: Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation
- Publication: Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research
- Publication: Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS
- Publication: Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
- Publication: Establishing a Reasonable Price for an Orphan Drug
- Publication: R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
- Publication: The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
- Publication: A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”
- Publication: Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence
- Publication: Real World Evidence for Coverage Decisions: Opportunities and Challenges
- Publication: Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
- Publication: Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
- Publication: Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?
- Publication: Incentives for New Drugs to Tackle Anti-Microbial Resistance
- Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
- Publication: Additional Elements of Value for Health Technology Assessment Decisions
- Publication: Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies
- Publication: How can HTA meet the needs of health system and government decision makers?
- Publication: Transferability of HTA
- Publication: HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?
- Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
- Publication: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
- Publication: Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study
- Publication: Policy Options for Formulary Development in Middle-income Countries
- Publication: Uncertainty and Risk in HTA Decision Making
- Publication: Four Case Studies to Explore the Added Value of Oxford AHSN
- Publication: How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
- Publication: Shaping the Research Agenda to Estimate Cost-effectiveness Thresholds for Decision Making
- Publication: Data Governance Arrangements for Real-World Evidence
- Publication: Multi-indication Pricing: Pros, Cons and Applicability to the UK
- Publication: International Decision Support Initiative (iDSI): Mapping of priority-setting in health in 17 low and middle countries across Asia, Latin America, and Africa
- Publication: Comparative and Relative Effectiveness: A Challenge For Health Systems, Regulators, or Pharmaceutical Companies?
- Publication: The Expanding Value Footprint of Oncology Treatments
- Publication: What is the Role of HTA for Biosimilars?
- Publication: Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold
- Publication: Exploring the link between health and wealth in decision making
- Publication: The R&D Cost of a New Medicine
- Publication: Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?
- Publication: The Use of Pay-for-Performance for Drugs: Can It Improve Incentives for Innovation?
- Publication: Operationalising Value Based Pricing of Medicines: A Taxonomy of Approaches
- Publication: New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy Options
- Publication: Incentives for R&D for New Antimicrobial Drugs
- Publication: Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
- Publication: The Evolution of HTA in Emerging Markets Health Care Systems: Analysis to Support a Policy Response
- Publication: Biosimilars: How Much Entry and Price Competition Will Result?
- Publication: Using QALYs in Cancer: Review of the Methodological Limitations
- Publication: Researching the Relative Efficacy and Relative Effectiveness of Medicines across Europe
- Publication: New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
- Publication: Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience
- Publication: The Market for Biosimilars: Evolution and Policy Options
- Publication: Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions
- Publication: Three Challenges to Achieving Better Analysis for Better Decisions: Generalisability, Complexity and Thresholds
- Publication: Economic Post-Launch Studies: Matching the Desirable with the Feasible
- Publication: Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?
- Publication: Public Private Partnerships for Research and Development: Medicines and Vaccines for Diseases of Poverty
- Publication: Cost-Effectiveness Thresholds: Economic and ethical issues
- Publication: Influencing Prescribing in a Primary Care Led NHS
- Publication: Disease Management, the NHS and the Pharmaceutical Industry
- Publication: From Efficacy to Cost-Effectiveness
- Publication: Regulating Prices Paid by the NHS for Medicines Supplied by the UK-Based Pharmaceutical Industry
- Publication: Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?
- Publication: Value of the Pharmaceutical Industry to the UK Economy
- Publication: Financing Health Care in the UK: A Discussion of NERA’s Prototype Model to Replace the NHS
- Publication: Industrial Policy and the Pharmaceutical Industry
- Publication: The Ideas and Influence of Alan Williams: Be Reasonable – Do It My Way